Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Dorman, Curtis Lockshin

Premium

RXi Pharmaceuticals has appointed Paul Dorman and Curtis Lockshin to its board of directors.

Dorman is currently chairman and CEO of holding company DFB Pharmaceuticals, and he holds a BS in mechanical engineering from Tulane University and a JD from Loyola University.

Lockshin most recently served as an independent consultant to Opko Health, which recently sold its RNAi assets to RXi. Before that, he was vice president of corporate research and development initiatives for Opko.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.